和黄医药今日盘中股价大幅上涨5.03%，引起了市场广泛关注。
消息面上，公司公布的2025年全年业绩显示，股东应占净收益达到4.57亿美元，同比大幅增长1111.03%。尽管收入总额有所下降，但净利润的强劲表现，主要得益于核心业务盈利及出售非核心业务带来的收益，显著增强了投资者信心。
此外，公司在财报中提供了2026年肿瘤/免疫业务综合收入的积极指引，并披露了抗体靶向偶联药物平台进入临床试验阶段等研发进展，为未来增长注入动力。
和黄医药今日盘中股价大幅上涨5.03%，引起了市场广泛关注。
消息面上，公司公布的2025年全年业绩显示，股东应占净收益达到4.57亿美元，同比大幅增长1111.03%。尽管收入总额有所下降，但净利润的强劲表现，主要得益于核心业务盈利及出售非核心业务带来的收益，显著增强了投资者信心。
此外，公司在财报中提供了2026年肿瘤/免疫业务综合收入的积极指引，并披露了抗体靶向偶联药物平台进入临床试验阶段等研发进展，为未来增长注入动力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.